The identification of two important podocyte autoantigens—secretory phospholipase A2 receptor (PLA2R1) and thrombospondin type 1 domain containing 7A protein (THSD7A)—and detection of their autoantibodies in 60–80% and 5–10% of patients with membranous nephropathy, respectively [6, 7], were regarded as landmark discoveries in understanding the molecular pathomechanism of IMN. Here, PLA2R1 is linked to membranous glomerulonephritis.